Normopress (Amlodipine, Lisinopril)

Amlodipine and Lisinopril, the active ingredients in Normopress, are a calcium channel blocker and an ACE inhibitor presented as oral tablets for adult use. They work together to lower elevated blood pressure in patients with hypertension and help reduce cardiovascular risk through complementary mechanisms.

GNH USA supplies Normopress as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with a focus on quality assurance and regulatory compliance and reliable delivery across multiple regions.

Normopress, a combination antihypertensive, is used to manage high blood pressure and related cardiovascular conditions.

- Hypertension: lowers systolic and diastolic blood pressure in patients requiring dual therapy. - Resistant hypertension: provides additional control when monotherapy is insufficient. - Hypertensive patients with diabetes: improves blood pressure management while addressing cardiovascular risk.

Common and serious adverse reactions have been reported with the combination of amlodipine and lisinopril.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Peripheral edema: swelling of ankles or feet due to vasodilation. - Dizziness: sensation of light‑headedness, especially when standing. - Flushing: transient warmth and reddening of the skin. - Cough: dry throat irritation associated with ACE inhibition. - Fatigue: general tiredness or lack of energy.

Serious or Rare Side Effects: - Angioedema: rapid swelling of face, lips, tongue or airway requiring emergency care. - Severe hypotension: marked drop in blood pressure leading to fainting or shock. - Hyperkalemia: elevated blood potassium levels that may affect heart rhythm. - Liver enzyme elevation: increased ALT/AST indicating possible hepatic stress. - Neutropenia: reduced white blood cell count increasing infection risk.

When prescribing Normopress, clinicians should observe several precautionary measures to ensure patient safety. - Blood pressure monitoring: regularly assess to avoid excessive hypotension. - Renal function assessment: evaluate serum creatinine and eGFR before and during therapy. - Electrolyte balance: check potassium levels, especially if combined with potassium‑sparing agents. - Pregnancy avoidance: discontinue if patient becomes pregnant or plans pregnancy. - Concomitant drug review: avoid simultaneous use with other ACE inhibitors or ARBs. - Store at room temperature: keep tablets in the original container, protect from moisture and light.

Normopress may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Aliskiren in diabetic patients: combined use can cause renal impairment and hyperkalemia. - Dual ACE inhibitor or ARB therapy: increases risk of hypotension, kidney dysfunction, and hyperkalemia. - Potassium supplements or potassium‑sparing diuretics: may lead to dangerous hyperkalemia.

Moderate Interactions (Monitor Closely): - NSAIDs: can reduce antihypertensive effect and affect renal function. - Diuretics: may enhance hypotensive response; monitor blood pressure. - CYP3A4 inhibitors (e.g., clarithromycin): may increase amlodipine levels, leading to edema or dizziness.